BioCentury | Dec 31, 2020
Regulation

119 drugs added to China’s reimbursement list, which includes more domestic PD-1s

...and other newly added cancer drugs such as Btk inhibitor Brukinsa zanubrutinib from BeiGene and PARP...
...March 1, 2021, and remain valid until Dec. 31, 2022.TARGETSBtk – Bruton’s tyrosine kinasePARPPoly(ADP-ribose) polymerase PD-1...
...Btk) Programmed cell death 1 (PD-1) (PDCD1) (CD279) Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Poly(ADP-ribose) polymerase (PARP) NRDL...
BioCentury | Dec 4, 2020
Deals

Artios deal fourth for synthetic lethality in 2020: Data Byte

...Inc.  and Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) formed a joint venture to develop Impact’s PARP...
...$3 billion in license fees and milestones, plus royalties.TARGETSMAT2A - Methionine adenosyltransferase 2A PARP - Poly(ADP-ribose) polymerase...
BioCentury | Dec 3, 2020
Deals

Artios picks Germany’s Merck for first major pharma collaboration in synthetic lethality

...The U.K. biotech is led by Niall Martin, who established the PARP program that produced Lynparza   By Paul...
...that inhibit PARP work via synthetic lethality. While at KuDos Pharmaceuticals Ltd., Martin established the PARP...
...a three-target deal with Ideaya in June. GSK markets Zejula niraparib, one of four approved PARP...
BioCentury | Oct 31, 2020
Translation in Brief

A method to collect tumor-specific T cells; plus research from Heidelberg University, Black Diamond, KSQ and SynDevRx

...alone. KSQ plans to submit an IND for KSQ-4279 next year. AstraZeneca plc (LSE:AZN; NASDAQ:AZN) markets the PARP...
...inhibition in healthy mice.TARGETSAKT (AKT1; PKB; PKBA) – Protein kinase B MetAP2 – Methionine aminopeptidase 2 PARPPoly(ADP-ribose) polymerase PI3K...
...Scripps Research Institute Nanjing University Heidelberg University Black Diamond Therapeutics Inc. KSQ Therapeutics Inc. SynDevRx Inc. Ubiquitin specific peptidase 1 (USP1) Poly(ADP-ribose) polymerase (PARP) Protein...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...therapies including the EGFR inhibitor Tagrisso osimertinib, PARP...
BioCentury | Oct 2, 2020
Finance

Next stop IPO? Olema adds to momentum with $85M series C

...August 2015 to April 2019, the pharma gained FDA approvals of PD-L1 inhibitor Imfinzi durvalumab, PARP...
BioCentury | Sep 18, 2020
Management Tracks

Former AZ CMO Bohen brings his cancer chops to Olema

...NYSE:AZN) from August 2015 to April 2019, the pharma had FDA approvals of PD-L1 inhibitor Imfinzi durvalumab, PARP...
BioCentury | Sep 16, 2020
Finance

Zai aiming to gain dual listing via Hong Kong offering

...cancer treatments in China and nearby territories: PARP...
...a market cap of $5.9 billion.TARGETSPARPPoly(ADP-ribose) polymerase Paul...
BioCentury | Sep 15, 2020
Product Development

Data Bytes: Trodelvy leads TROP2 pack

...Immunomedics also is testing Trodelvy with PD-L1 inhibitor Tecentriq atezolizumab from Roche (SIX:ROG; OTCQX:RHHBY) and PARP...
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...Trodelvy’s use in combination with checkpoint inhibitors, PARP...
Items per page:
1 - 10 of 697